Last edition
News about "Orna Therapeutics "
Lilly’s acquisition of Orna Therapeutics aims to accelerate development of in vivo CAR-T therapies powered by engineered circular RNA and advanced lipid nanoparticle delivery platforms.
Orna Therapeutics | 10/02/2026 | By News Bureau
Orna Therapeutics Acquires ReNAgade to Strengthen Expertise in RNA Therapies
Orna Therapeutics has recently acquired ReNAgade Therapeutics, a pioneer in unlocking the potential of RNA therapeutics that demonstrated industry-leading delivery to multiple extra-hepatic cells in non-human primate (NHP) models over the past 18 months.
Orna Therapeutics | 27/05/2024 | By Aishwarya | 277
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy